Elvitegravir
- Generic Name
- Elvitegravir
- Brand Names
- Genvoya, Stribild
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23ClFNO5
- CAS Number
- 697761-98-1
- Unique Ingredient Identifier
- 4GDQ854U53
- Background
Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) used for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults. Because integrase is necessary for viral replication, inhibition prevents the integration of HIV-1 DNA into the host genome and thereby blocks the formation of the ...
- Indication
Elvitegravir in combination with an HIV protease inhibitor coadministered with ritonavir and with other antiretroviral drug(s) is indicated for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants
- Conditions
- Interventions
- First Posted Date
- 2013-08-15
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 31
- Registration Number
- NCT01923311
- Locations
- 🇿🇦
Be Part Yoluntu Centre, Cape Town, South Africa
🇮🇹Universita degli Studi di Pavia - Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
🇺🇬Joint Clinical Research Centre, Kampala, Uganda
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir
- Conditions
- Interventions
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2016-05-30
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 724
- Registration Number
- NCT00708162
- Locations
- 🇺🇸
Whitman-Walker Clinic, Washington, District of Columbia, United States
🇺🇸Orlando Immunology Center, Orlando, Florida, United States
🇺🇸Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2016-04-25
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 192
- Registration Number
- NCT00445146
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.